Events3rd International Electronic Conference on Medicinal Chemistry
Published
This submission belongs to the session A. ECMC-3 of the event 3rd International Electronic Conference on Medicinal Chemistry
Published date
01 Nov, 2017
Citation
Elodie Lohou, N. André SASAKI, Agnès BOULLIER, Pascal SONNET, Multifunctional Diamine AGE/ALE Inhibitors with Promising Properties for Treating Alzheimer's Disease, in Proceedings of 3rd International Electronic Conference on Medicinal Chemistry, 1 November–30 November 2017, MDPI: Basel, Switzerland, doi: 10.3390/ecmc-3-04655
Share
Email
Facebook
Twitter
LinkedIn

Multifunctional Diamine AGE/ALE Inhibitors with Promising Properties for Treating Alzheimer's Disease

image
image
1. Laboratoire AGIR (AGents Infectieux Résistance et chimiothérapie), UR 4294, Université de Picardie Jules Verne (UPJV), UFR de pharmacie, 1 rue des Louvels, F-80037, Amiens Cedex 1, France.
2. Université de Picardie Jules Verne, UFR de Médecine, 1 Rue des Louvels, F-80037, Amiens Cedex 01 / INSERM U1088, Centre Universitaire de Recherche en Santé (CURS), CHU Amiens Picardie, Avenue René Laënnec - Salouel, F-80054, Amiens Cedex 01, France.
Abstract

Reactive carbonyl species (RCS) such as methylglyoxal (MGO) or malondialdehyde (MDA) are endogenously formed during the sugar glycoxidation and lipid peroxidation of polyunsaturated fatty acids induced by oxidative stress exacerbation. Their condensation with amino groups of tissue proteins gives AGE (Advanced Glycation Endproducts) and ALE (Advanced Lipid peroxidation Endproducts). In Alzheimer's disease (AD), extensive AGE/ALE accumulation has been reported in extracellular amyloid β (Aβ) plaques and intracellular tau-associated neurofibrillary tangles. Indeed, a critical imbalance between cerebral reactive oxygen species (ROS) production and endogenous antioxidant capacities associated with biometal dyshomeostasis has been suggested to be a driving force for AD onset and progression. Aβ-oligomers induce oxidative stress whereas transition metals (Zn2+, Cu2+ and Fe3+) stimulate Aβ aggregation and APP (amyloid precursor protein) processing. Consequently, RCS accumulation takes part in the vicious downward redox amyloid spiral leading to neurodegeneration.1,2 AGE/ALE are now considered to play an important role at the late stages of AD pathogenesis through three main mechanisms.3 First, glycated Aβ cross-linking promotion accelerates its deposition and its protease resistance. Secondly, AGE/ALE formation not only accelerates tau hyperphosphorylation, disturbs the neuronal membrane depolarization process and the glucose transport but also exacerbates glutamate-mediated excitotoxicity. Thirdly, AGE promote via their receptors RAGE oxidative stress and inflammation as well as cell apoptosis.

Taking into account the multifactorial pathogenesis of AD, we designed new multifunctional drugs that are simultaneously able to trap RCS (primary vicinal diamine function) as well as ROS and biometals (phenolic acid or hydroxypyridinone moiety).4 In the presentation, synthesis of these new promising hybrid AGE/ALE inhibitors and evaluation of their physicochemical and biological properties (carbonyl trapping capacity, antioxidant activity, Cu2+-chelating capacity, cytotoxicity and protective effect against in vitro MGO-induced apoptosis in the model AD cell-line PC12) are reported.

References

  1. D.A. Butterfield, J. Drake, C. Pocernich and A. Castegna, Trends Mol. Med., 2001, 7, 548-554.
  2. A. Tiiman, P. Palumaa and V. Tougu, Neurochem. Int., 2013, 62, 367-378.
  3. M. Krautwald and G. Münch, Exp. Gerontol., 2010, 45, 744-751.
  4. E. Lohou, N.A. Sasaki, A. Boullier and P. Sonnet, Eur. J. Med. Chem., 2016, 122, 702-722.
Keywords
AGE/ALE inhibitors
carbonyl stress
oxidative stress
biometal dyshomeostasis
Alzheimer's disease
hydroxypyridinone
phenolic acids
Manuscript
Poster
sciforum-014414.pdf
Multivalent Engineered RNA Molecules that Interfere with Hepatitis C Virus Translation and Replication
Novel Gold Complexes with Nitrogen Acyclic Carbenes and their Applications as Anticancer Agents